Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
|Articles|September 2, 2013
- Pharmaceutical Technology-09-02-2013
- Volume 37
- Issue 9
Pharmaceutical Technology, September 2013 Issue (PDF)
Click the title above to open the Pharmaceutical Technology September 2013 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 13 years ago
The Importance of Continued Investment in R&Dabout 13 years ago
FDA Works to Secure Drug Supply Chainabout 13 years ago
Outsourcing Partnerships for CMC Developmentabout 13 years ago
MF40 Automated Punch and Die Polishing Machineabout 13 years ago
Quality by Design in APIsabout 13 years ago
Connecting People, Science, and Regulationabout 13 years ago
Effective and Efficient Weighing of Potent Compoundsabout 13 years ago
EU Raises API Standards: A Curse in Disguise?about 13 years ago
The Importance of Characterization in Biosimilars Developmentabout 13 years ago
Omega Design Corporation Introduces LabelSync 450Advertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement